Mutational Analysis of BRAF Inhibitor–Associated Squamoproliferative Lesions Britt Clynick, Tania Tabone, Kathryn Fuller, Wendy Erber, Katie Meehan, Michael.

Slides:

Advertisements

Similar presentations

Functional Analysis of the Neurofibromatosis Type 2 Protein by Means of Disease- Causing Point Mutations Renee P. Stokowski, David R. Cox The American.

Advertisements

Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification.

Nine Novel Germline Gene Variants in the RET Proto-Oncogene Identified in Twelve Unrelated Cases Syed A. Ahmed, Karen Snow-Bailey, W. Edward Highsmith,

Development of a Novel One-Tube Isothermal Reverse Transcription Thermophilic Helicase-Dependent Amplification Platform for Rapid RNA Detection James Goldmeyer,

Telomerase Activity and Expression of Telomerase RNA Component and Telomerase Catalytic Subunit Gene in Cervical Cancer Kenji Nakano, Elizabeth Watney,

CyclinD1/CyclinD3 Ratio by Real-Time PCR Improves Specificity for the Diagnosis of Mantle Cell Lymphoma Carol D. Jones, Katherine H. Darnell, Roger A.

Quantification of Parvovirus B19 DNA Using COBAS AmpliPrep Automated Sample Preparation and LightCycler Real-Time PCR Stefan Schorling, Gunnar Schalasta,

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Volume 18, Issue 6, Pages e1 (November 2017)

Primary cutaneous mucinous carcinoma of the breast

Statistical Considerations for Immunohistochemistry Panel Development after Gene Expression Profiling of Human Cancers Rebecca A. Betensky, Catherine.

CD47 expression for in situ and invasive cutaneous epithelial lesions

Vida Kocbek, Katja Vouk, Nick A. Bersinger, Michael D

Evaluation of the Real-Q BRAF V600E Detection Assay in Fine-Needle Aspiration Samples of Thyroid Nodules Kyung Sun Park, Young L. Oh, Chang-Seok Ki,

Hybrid Model Integrating Immunohistochemistry and Expression Profiling for the Classification of Carcinomas of Unknown Primary Site Barbara A. Centeno,

Laboratory Guidelines for Detection, Interpretation, and Reporting of Maternal Cell Contamination in Prenatal Analyses Narasimhan Nagan, Nicole E. Faulkner,

Eligibility Criteria and Genetic Testing Results from a High-Risk Cohort for Hereditary Breast and Ovarian Cancer Syndrome in Southeastern Ontario Ricardo.

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Neal I. Lindeman, Philip T. Cagle, Mary.

Molecular Genetics of Pediatric Soft Tissue Tumors

ALK FISH and IHC: You Cannot Have One without the Other

Genetic Profiling of BRAF Inhibitor–Induced Keratoacanthomas Reveals No Induction of MAP Kinase Pathway Expression Rajan P. Kulkarni, Seema Plaisier,

Nicole M. Cassler, MD, Jason D. Marquart, MD, Corey A. Carter, MD

Exploring the relationship between natural killer cells and cutaneous squamous cell carcinoma development Muneeb Ilyas, BSc, Collin M. Costello, BS,

Young H. Lim, Jonathan M. Fisher, Marcus W. Bosenberg, Keith A

Mutation Screening in Juvenile Polyposis Syndrome

Joanna Wang, Chetan Bettegowda The Journal of Molecular Diagnostics

Increased Sensitivity of the Roche COBAS AMPLICOR HCV Test, Version 2

Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype Cristina Pellegrini, Lucia.

Jeung-Yeal Ahn, Katie Seo, Olga Weinberg, Scott D. Boyd, Daniel A

A Lean Laboratory The Journal of Molecular Diagnostics

ALK Status Testing in Non–Small Cell Lung Carcinoma

Digital metastasis of tongue squamous cell carcinoma

Patrick R. Murray The Journal of Molecular Diagnostics

William L. Gerald, M.D., Ph.D, 1954–2008

Sean C. Murphy, Daniel R. Hoogestraat, Dhruba J

Volume 3, Issue 6, Pages (November 2017)

The Human Androgen Receptor X-Chromosome Inactivation Assay for Clonality Diagnostics of Natural Killer Cell Proliferations Michaël Boudewijns, Jacques.

Driver Gene Mutations in Stools of Colorectal Carcinoma Patients Detected by Targeted Next-Generation Sequencing Gemma Armengol, Virinder K. Sarhadi,

A Diagnostic Dilemma in a Patient with Polyarthritis

Comparison of KRAS Mutation Analysis and FISH for Detecting Pancreatobiliary Tract Cancer in Cytology Specimens Collected During Endoscopic Retrograde.

BRAF Mutation Testing in Solid Tumors

Skin Biopsy Is a Practical Approach for the Clinical Diagnosis and Molecular Genetic Analysis of X-Linked Alport's Syndrome Fang Wang, Dan Zhao, Jie.

Kavitha K. Reddy Journal of Investigative Dermatology

Plasmacytoid dendritic cell involvement in the host response against keratoacanthoma Ossama Abbas, MD, Lama Hussein, MD, Mazen Kurban, MD, Abdul-Ghani.

Multiplex Bead Suspension Array for Screening Neisseria gonorrhoeae Antibiotic Resistance Genetic Determinants in Noncultured Clinical Samples Sergey.

The Molecular Pathology of Primary Immunodeficiencies

Report of New Haplotype for ABCC2 Gene

The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice Daniele Viarisio, Karin Müller-Decker,

Genetic Heterogeneity in Saliva from Patients with Oral Squamous Carcinomas Adel K. El-Naggar, Li Mao, Gregg Staerkel, Madelene M. Coombes, Susan L. Tucker,

Vida Kocbek, Katja Vouk, Nick A. Bersinger, Michael D

Molecular Monitoring of Chronic Myeloid Leukemia

Ayalew Tefferi, Pierre Noel, Curtis A. Hanson

Avoiding Pitfalls in Molecular Genetic Testing

Vikas K. Goel, Alexander J. F. Lazar, Carla L. Warneke, Mark S

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers Wenhsiang Wen, Wangjuh (Sting) Chen, Nick Xiao, Ryan.

Bryan K. Sun, Andrea Saggini, Kavita Y

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Carrie C. Lubitz, Sareh Parangi, Tammy M. Holm, M

Karen Snow-Bailey, Ph.D., 1961–2006

Extra Alleles in FMR1 Triple-Primed PCR

Topical 5-Fluorouracil Elicits Regressions of BRAF Inhibitor–Induced Cutaneous Squamous Cell Carcinoma Amaya Viros, Robert Hayward, Matthew Martin, Sharona.

Varying Mutational Alterations in Multiple Primary Melanomas

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Volume 82, Issue 9, Pages (November 2012)

Angiotensin I-Converting Enzyme

Monique A. Johnson, Marvin J. Yoshitomi, C. Sue Richards

Quiz Page January 2010 American Journal of Kidney Diseases

Volume 3, Issue 6, Pages (November 2017)

Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAF Alois H. Lang, Heinz Drexel, Simone Geller-Rhomberg,

Lung Adenocarcinoma Harboring Mutations in the ERBB2 Kinase Domain

Presentation transcript:

Mutational Analysis of BRAF Inhibitor–Associated Squamoproliferative Lesions Britt Clynick, Tania Tabone, Kathryn Fuller, Wendy Erber, Katie Meehan, Michael Millward, Benjamin A. Wood, Nathan T. Harvey The Journal of Molecular Diagnostics Volume 17, Issue 6, Pages 644-651 (November 2015) DOI: 10.1016/j.jmoldx.2015.05.009 Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 1 Graphical representation of the number of lesions containing mutations for each of the genes for which at least one mutation was identified. A: All lesions. B: BRAF inhibitor (BRAFi)–associated lesions. BAVK, BRAF inhibitor–associated verrucous keratosis; KA, keratoacanthoma; SCC, squamous cell carcinoma. The Journal of Molecular Diagnostics 2015 17, 644-651DOI: (10.1016/j.jmoldx.2015.05.009) Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 2 Representative examples of both the hematoxylin and eosin (H&E) appearances and immunohistochemical (IHC) staining for the phosphorylated form of extracellular signal–related kinase (pERK) in a BRAF inhibitor–associated verrucous keratosis (A and B, respectively), a keratoacanthoma (C and D, respectively), and a squamous cell carcinoma (E and F, respectively). All three lesions originated from patients undergoing treatment with a BRAF inhibitor. A, C, and E: H&E staining. B, D, and F: IHC staining for pERK. The Journal of Molecular Diagnostics 2015 17, 644-651DOI: (10.1016/j.jmoldx.2015.05.009) Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions